{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:07:38Z","timestamp":1790654858557,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23-004"],"award-info":[{"award-number":["23-004"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["17ck0106251"],"award-info":[{"award-number":["17ck0106251"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Center Research and Development Fund","award":["23-A-23"],"award-info":[{"award-number":["23-A-23"]}]},{"name":"National Cancer Center Research and Development Fund","award":["26-A-24"],"award-info":[{"award-number":["26-A-24"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00277-020-04245-6","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T21:02:42Z","timestamp":1599080562000},"page":"2787-2800","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia"],"prefix":"10.1007","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4450-0106","authenticated-orcid":false,"given":"Hitoshi","family":"Minamiguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Asou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Sakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Dobashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehisa","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Hagihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumichi","family":"Fujimaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamitsu","family":"Yanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Iwanaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2378-7865","authenticated-orcid":false,"given":"Yukio","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Ohtake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Naoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7504-6677","authenticated-orcid":false,"given":"Akihiro","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Japan Adult Leukemia Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,2]]},"reference":[{"key":"4245_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/shem.2001.20861","volume":"38","author":"G Avvisati","year":"2001","unstructured":"Avvisati G, Lo Coco F, Mandelli F (2001) Acute promyelocytic leukemia: clinical and morphologic features and prognostic factors. Semin Hematol 38:4\u201312","journal-title":"Semin Hematol"},{"key":"4245_CR2","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/sj.leu.2402721","volume":"16","author":"D Grimwade","year":"2002","unstructured":"Grimwade D, Lo Coco F (2002) Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 16:1959\u20131973. https:\/\/doi.org\/10.1038\/sj.leu.2402721","journal-title":"Leukemia"},{"key":"4245_CR3","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1182\/blood.v99.3.759","volume":"99","author":"MS Tallman","year":"2002","unstructured":"Tallman MS, Nabhan C, Feusner JH, Rowe JM (2002) Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 99:759\u2013767. https:\/\/doi.org\/10.1182\/blood.v99.3.759","journal-title":"Blood"},{"key":"4245_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1182\/blood-2006-08-043992","volume":"110","author":"N Asou","year":"2007","unstructured":"Asou N, Kishimoto Y, Kiyoi H et al (2007) A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RAR\u03b1 transcript after consolidation therapy: the Japan adult leukemia study group (JALSG) APL97 study. Blood 110:59\u201366. https:\/\/doi.org\/10.1182\/blood-2006-08-043992","journal-title":"Blood"},{"key":"4245_CR5","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1182\/blood-2008-05-159632","volume":"112","author":"MA Sanz","year":"2008","unstructured":"Sanz MA, Montesinos P, Vellenga E et al (2008) Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA group. Blood 112:3130\u20133134. https:\/\/doi.org\/10.1182\/blood-2008-05-159632","journal-title":"Blood"},{"key":"4245_CR6","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1182\/blood-2009-07-233387","volume":"115","author":"L Ad\u00e8s","year":"2010","unstructured":"Ad\u00e8s L, Guerci A, Raffoux E et al (2010) Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood 115:1690\u20131696. https:\/\/doi.org\/10.1182\/blood-2009-07-233387","journal-title":"Blood"},{"key":"4245_CR7","doi-asserted-by":"publisher","first-page":"4716","DOI":"10.1182\/blood-2010-08-302950","volume":"117","author":"G Avvisati","year":"2011","unstructured":"Avvisati G, Lo-Coco F, Paoloni FP et al (2011) AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood 117:4716\u20134725. https:\/\/doi.org\/10.1182\/blood-2010-08-302950","journal-title":"Blood"},{"key":"4245_CR8","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1182\/blood-2010-03-276196","volume":"116","author":"F Lo-Coco","year":"2010","unstructured":"Lo-Coco F, Avvisati G, Vignetti M et al (2010) Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA group. Blood 116:3171\u20133179. https:\/\/doi.org\/10.1182\/blood-2010-03-276196","journal-title":"Blood"},{"key":"4245_CR9","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1182\/blood-2010-02-269621","volume":"116","author":"BL Powell","year":"2010","unstructured":"Powell BL, Moser B, Stock W et al (2010) Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: north American leukemia intergroup study C9710. Blood 116:3751\u20133757. https:\/\/doi.org\/10.1182\/blood-2010-02-269621","journal-title":"Blood"},{"key":"4245_CR10","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/leu.2012.360","volume":"27","author":"AK Burnett","year":"2013","unstructured":"Burnett AK, Hills RK, Grimwade D et al (2013) Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial. Leukemia 27:843\u2013851. https:\/\/doi.org\/10.1038\/leu.2012.360","journal-title":"Leukemia"},{"key":"4245_CR11","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/ajh.23451","volume":"88","author":"L Ad\u00e8s","year":"2013","unstructured":"Ad\u00e8s L, Chevret S, Raffoux E et al (2013) Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and daunorubicin in the treatment of nonelderly APL patients. Am J Hematol 88:556\u2013559. https:\/\/doi.org\/10.1002\/ajh.23451","journal-title":"Am J Hematol"},{"key":"4245_CR12","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","volume":"16","author":"AK Burnett","year":"2015","unstructured":"Burnett AK, Russell NH, Hills RK et al (2015) Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol 16:1295\u20131305. https:\/\/doi.org\/10.1016\/S1470-2045(15)00193-X","journal-title":"Lancet Oncol"},{"key":"4245_CR13","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1016\/S2352-3026(15)00115-5","volume":"2","author":"HJ Iland","year":"2015","unstructured":"Iland HJ, Collins M, Bradstock K et al (2015) Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and lymphoma group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematol 2:e357\u2013e366. https:\/\/doi.org\/10.1016\/S2352-3026(15)00115-5","journal-title":"Lancet Haematol"},{"key":"4245_CR14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","volume":"35","author":"U Platzbecker","year":"2017","unstructured":"Platzbecker U, Avvisati G, Cicconi L et al (2017) Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol 35:605\u2013612. https:\/\/doi.org\/10.1200\/JCO.2016.67.1982","journal-title":"J Clin Oncol"},{"key":"4245_CR15","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.3324\/haematol.2018.198614","volume":"103","author":"L Ad\u00e8s","year":"2018","unstructured":"Ad\u00e8s L, Thomas X, Bresler AG et al (2018) Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group. Haematologica 103:2033\u20132039. https:\/\/doi.org\/10.3324\/haematol.2018.198614","journal-title":"Haematologica"},{"key":"4245_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/leu.2017.178","volume":"32","author":"D Mart\u00ednez-Cuadr\u00f3n","year":"2018","unstructured":"Mart\u00ednez-Cuadr\u00f3n D, Montesinos P, Vellenga E et al (2018) Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy. Leukemia 32:21\u201329. https:\/\/doi.org\/10.1038\/leu.2017.178","journal-title":"Leukemia"},{"key":"4245_CR17","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1016\/j.thromres.2018.01.038","volume":"164","author":"S Mantha","year":"2018","unstructured":"Mantha S, Tallman MS, Devlin SM, Soff GA (2018) Predictive factors of fatal bleeding in acute promyelocytic leukemia. Thromb Res 164:S98\u2013S102. https:\/\/doi.org\/10.1016\/j.thromres.2018.01.038","journal-title":"Thromb Res"},{"key":"4245_CR18","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/s41375-018-0139-4","volume":"32","author":"S Kayser","year":"2018","unstructured":"Kayser S, Schlenk RF, Platzbecker U (2018) Management of patients with acute promyelocytic leukemia. Leukemia 32:1277\u20131294. https:\/\/doi.org\/10.1038\/s41375-018-0139-4","journal-title":"Leukemia"},{"key":"4245_CR19","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","volume":"133","author":"MA Sanz","year":"2019","unstructured":"Sanz MA, Fenaux P, Tallman MS et al (2019) Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood 133:1630\u20131643. https:\/\/doi.org\/10.1182\/blood-2019-01-894980","journal-title":"Blood"},{"key":"4245_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/bjh.16151","volume":"187","author":"M Stahl","year":"2019","unstructured":"Stahl M, Tallman MS (2019) Differentiation syndrome in acute promyelocytic leukaemia. Br J Haematol 187:157\u2013162. https:\/\/doi.org\/10.1111\/bjh.16151","journal-title":"Br J Haematol"},{"key":"4245_CR21","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1182\/blood.V75.11.2112.2112","volume":"75","author":"F Rodeghiero","year":"1990","unstructured":"Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F (1990) Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 75:2112\u20132117","journal-title":"Blood"},{"key":"4245_CR22","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1182\/blood-2007-07-100669","volume":"111","author":"J de la Serna","year":"2008","unstructured":"de la Serna J, Montesinos P, Vellenga E et al (2008) Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 111:3395\u20133402. https:\/\/doi.org\/10.1182\/blood-2007-07-100669","journal-title":"Blood"},{"key":"4245_CR23","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.1182\/blood-2010-01-266007","volume":"115","author":"MA Sanz","year":"2010","unstructured":"Sanz MA, Montesinos P, Rayon C et al (2010) Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 115:5137\u20135146. https:\/\/doi.org\/10.1182\/blood-2010-01-266007","journal-title":"Blood"},{"key":"4245_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1600-0609.1995.tb01630.x","volume":"54","author":"S Gillis","year":"1995","unstructured":"Gillis S, Dann EJ, Eldor A (1995) Low molecular weight heparin in the prophylaxis and treatment of disseminated intravascular coagulation in acute promyelocytic leukemia. Eur J Haematol 54:59\u201360. https:\/\/doi.org\/10.1111\/j.1600-0609.1995.tb01630.x","journal-title":"Eur J Haematol"},{"key":"4245_CR25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/0049-3848(93)90109-2","volume":"72","author":"N Sakuragawa","year":"1993","unstructured":"Sakuragawa N, Hasegawa H, Maki M, Nakagawa M, Nakashima M (1993) Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC) \u2014 a multicenter co-operative double-blind trial in comparison with heparin. Thromb Res 72:475\u2013500. https:\/\/doi.org\/10.1016\/0049-3848(93)90109-2","journal-title":"Thromb Res"},{"key":"4245_CR26","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1097\/00003246-200005000-00027","volume":"28","author":"T Nishiyama","year":"2000","unstructured":"Nishiyama T, Matsukawa T, Hanaoka K (2000) Is protease inhibitor a choice for the treatment of pre- or mild disseminated intravascular coagulation? Crit Care Med 28:1419\u20131422. https:\/\/doi.org\/10.1097\/00003246-200005000-00027","journal-title":"Crit Care Med"},{"key":"4245_CR27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s12185-018-02567-w","volume":"109","author":"D Minakata","year":"2019","unstructured":"Minakata D, Fujiwara SI, Ikeda T et al (2019) Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies. Int J Hematol 109:141\u2013146. https:\/\/doi.org\/10.1007\/s12185-018-02567-w","journal-title":"Int J Hematol"},{"key":"4245_CR28","doi-asserted-by":"publisher","unstructured":"Nieuwenhuis HK, Sixma JJ (1986) Treatment of disseminated intravascular coagulation in acute promyelocytic leukemia with low molecular weight heparinoid Org 10172. Cancer 58:761\u2013764. https:\/\/doi.org\/10.1002\/1097-0142(19860801)58:3 < 761::aid-cncr2820580325 > 3.0.co;2\u20136","DOI":"10.1002\/1097-0142(19860801)58:3"},{"key":"4245_CR29","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1159\/000501818","volume":"143","author":"D Minakata","year":"2020","unstructured":"Minakata D, Fujiwara S, Hayakawa J et al (2020) Comparison of danaparoid sodium and synthetic protease inhibitors for the treatment of disseminated intravascular coagulation associated with hematological malignancies: a retrospective analysis. Acta Haematol 143:250\u2013259. https:\/\/doi.org\/10.1159\/000501818","journal-title":"Acta Haematol"},{"key":"4245_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1538-7836.2006.02267.x","volume":"5","author":"H Saito","year":"2007","unstructured":"Saito H, Maruyama I, Shimazaki S et al (2007) Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5:31\u201341. https:\/\/doi.org\/10.1111\/j.1538-7836.2006.02267.x","journal-title":"J Thromb Haemost"},{"key":"4245_CR31","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.leukres.2012.08.012","volume":"36","author":"T Ikezoe","year":"2012","unstructured":"Ikezoe T, Takeuchi A, Isaka M et al (2012) Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascular coagulation. Leuk Res 36:1398\u20131402. https:\/\/doi.org\/10.1016\/j.leukres.2012.08.012","journal-title":"Leuk Res"},{"key":"4245_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012981","volume":"97","author":"M Ookura","year":"2018","unstructured":"Ookura M, Hosono N, Tasaki T et al (2018) Successful treatment of disseminated intravascular coagulation by recombinant human soluble thrombomodulin in patients with acute myeloid leukemia. Medicine (Baltimore) 97:e12981. https:\/\/doi.org\/10.1097\/MD.0000000000012981","journal-title":"Medicine (Baltimore)"},{"key":"4245_CR33","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1200\/JCO.2013.53.3570","volume":"32","author":"K Shinagawa","year":"2014","unstructured":"Shinagawa K, Yanada M, Sakura T et al (2014) Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trial. J Clin Oncol 32:3729\u20133735. https:\/\/doi.org\/10.1200\/JCO.2013.53.3570","journal-title":"J Clin Oncol"},{"key":"4245_CR34","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41375-018-0233-7","volume":"33","author":"A Takeshita","year":"2019","unstructured":"Takeshita A, Asou N, Atsuta Y et al (2019) Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study. Leukemia 33:358\u2013370. https:\/\/doi.org\/10.1038\/s41375-018-0233-7","journal-title":"Leukemia"},{"key":"4245_CR35","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.3390\/cancers12061444","volume":"12","author":"A Takeshita","year":"2020","unstructured":"Takeshita A, Asou N, Atsuta Y et al (2020) Impact of CD56 continuously recognizable as prognostic value of acute promyelocytic leukemia: results of multivariate analyses in the Japan adult leukemia study group (JALSG)-APL204 study and a review of the literature. Cancers 12:1444. https:\/\/doi.org\/10.3390\/cancers12061444","journal-title":"Cancers"},{"key":"4245_CR36","doi-asserted-by":"publisher","first-page":"278","DOI":"10.7326\/0003-4819-120-4-199402150-00004","volume":"120","author":"SR Frankel","year":"1994","unstructured":"Frankel SR, Eardley A, Heller G et al (1994) All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York study. Ann Intern Med 120:278\u2013286. https:\/\/doi.org\/10.7326\/0003-4819-120-4-199402150-00004","journal-title":"Ann Intern Med"},{"key":"4245_CR37","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1182\/blood-2016-10-747170","volume":"129","author":"S Mantha","year":"2017","unstructured":"Mantha S, Goldman DA, Devlin SM et al (2017) Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood 129:1763\u20131767. https:\/\/doi.org\/10.1182\/blood-2016-10-747170","journal-title":"Blood"},{"key":"4245_CR38","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","volume":"113","author":"P Montesinos","year":"2009","unstructured":"Montesinos P, Bergua JM, Vellenga E et al (2009) Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 113:775\u2013783. https:\/\/doi.org\/10.1182\/blood-2008-07-168617","journal-title":"Blood"},{"key":"4245_CR39","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"4245_CR40","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1182\/blood.V88.4.1390.bloodjournal8841390","volume":"88","author":"G Avvisati","year":"1996","unstructured":"Avvisati G, Lo Coco F, Diverio D et al (1996) AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 88:1390\u20131398","journal-title":"Blood"},{"key":"4245_CR41","first-page":"1014","volume":"90","author":"F Mandelli","year":"1997","unstructured":"Mandelli F, Diverio D, Avvisati G et al (1997) Molecular remission in PML\/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica cooperative groups. Blood 90:1014\u20131021","journal-title":"Blood"},{"key":"4245_CR42","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1056\/NEJM199710093371501","volume":"337","author":"MS Tallman","year":"1997","unstructured":"Tallman MS, Andersen JW, Schiffer CA et al (1997) All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021\u20131028. https:\/\/doi.org\/10.1056\/NEJM199710093371501","journal-title":"N Engl J Med"},{"key":"4245_CR43","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1200\/JCO.1998.16.1.78","volume":"16","author":"N Asou","year":"1998","unstructured":"Asou N, Adachi K, Tamura J et al (1998) Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan adult leukemia study group. J Clin Oncol 16:78\u201385. https:\/\/doi.org\/10.1200\/JCO.1998.16.1.78","journal-title":"J Clin Oncol"},{"key":"4245_CR44","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1182\/blood-2011-04-346437","volume":"118","author":"JH Park","year":"2011","unstructured":"Park JH, Qiao B, Panageas KS et al (2011) Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 118:1248\u20131254. https:\/\/doi.org\/10.1182\/blood-2011-04-346437","journal-title":"Blood"},{"key":"4245_CR45","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3324\/haematol.2011.046490","volume":"97","author":"JS McClellan","year":"2012","unstructured":"McClellan JS, Kohrt HE, Coutre S et al (2012) Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica 97:133\u2013136. https:\/\/doi.org\/10.3324\/haematol.2011.046490","journal-title":"Haematologica"},{"key":"4245_CR46","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1007\/s00277-017-3096-5","volume":"96","author":"Y Lou","year":"2017","unstructured":"Lou Y, Ma Y, Sun J et al (2017) Effectivity of a modified Sanz risk model for early death prediction in patients with newly diagnosed acute promyelocytic leukemia. Ann Hematol 96:1793\u20131800. https:\/\/doi.org\/10.1007\/s00277-017-3096-5","journal-title":"Ann Hematol"},{"key":"4245_CR47","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/leu.2017.71","volume":"31","author":"S Lehmann","year":"2017","unstructured":"Lehmann S, Deneberg S, Antunovic P et al (2017) Early death rates remain high in high-risk APL: update from the Swedish acute leukemia registry 1997-2013. Leukemia 31:1457\u20131459. https:\/\/doi.org\/10.1038\/leu.2017.71","journal-title":"Leukemia"},{"key":"4245_CR48","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/ejh.13229","volume":"102","author":"JM N\u00f8rgaard","year":"2019","unstructured":"N\u00f8rgaard JM, Friis LS, Kristensen JS et al (2019) Addressing the room for improvement in management of acute promyelocytic leukemia. Eur J Haematol 102:479\u2013485. https:\/\/doi.org\/10.1111\/ejh.13229","journal-title":"Eur J Haematol"},{"key":"4245_CR49","first-page":"1192","volume":"94","author":"P Fenaux","year":"1999","unstructured":"Fenaux P, Chastang C, Chevret S et al (1999) A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group Blood 94:1192\u20131200","journal-title":"The European APL Group Blood"},{"key":"4245_CR50","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1046\/j.1365-2141.2000.01936.x","volume":"108","author":"E Di Bona","year":"2000","unstructured":"Di Bona E, Avvisati G, Castaman G et al (2000) Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol 108:689\u2013695","journal-title":"Br J Haematol"},{"key":"4245_CR51","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.thromres.2004.11.001","volume":"116","author":"N Dally","year":"2005","unstructured":"Dally N, Hoffman R, Haddad N, Sarig G, Rowe JM, Brenner B (2005) Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia\u2014a single center experience in 34 patients. Thromb Res 116:109\u2013114. https:\/\/doi.org\/10.1016\/j.thromres.2004.11.001","journal-title":"Thromb Res"},{"key":"4245_CR52","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1600-0609.2006.00803.x","volume":"78","author":"M Yanada","year":"2007","unstructured":"Yanada M, Matsushita T, Asou N et al (2007) Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol 78:213\u2013219. https:\/\/doi.org\/10.1111\/j.1600-0609.2006.00803.x","journal-title":"Eur J Haematol"},{"key":"4245_CR53","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.leukres.2010.05.022","volume":"35","author":"DY Kim","year":"2011","unstructured":"Kim DY, Lee JH, Kim SD et al (2011) Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia. Leuk Res 35:152\u2013158. https:\/\/doi.org\/10.1016\/j.leukres.2010.05.022","journal-title":"Leuk Res"},{"key":"4245_CR54","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1600-0609.2011.01747.x","volume":"88","author":"H Chang","year":"2012","unstructured":"Chang H, Kuo MC, Shih LY et al (2012) Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia. Eur J Haematol 88:321\u2013328. https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01747.x","journal-title":"Eur J Haematol"},{"key":"4245_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-013-0478-y","volume":"30","author":"M Mitrovic","year":"2013","unstructured":"Mitrovic M, Suvajdzic N, Bogdanovic A et al (2013) International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation \u22656: a new predictor of hemorrhagic early death in acute promyelocytic leukemia. Med Oncol 30:478. https:\/\/doi.org\/10.1007\/s12032-013-0478-y","journal-title":"Med Oncol"},{"key":"4245_CR56","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1007\/s00277-017-3042-6","volume":"96","author":"O Abla","year":"2017","unstructured":"Abla O, Ribeiro RC, Testi AM et al (2017) Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy. Ann Hematol 96:1449\u20131456. https:\/\/doi.org\/10.1007\/s00277-017-3042-6","journal-title":"Ann Hematol"},{"key":"4245_CR57","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.2147\/CMAR.S167686","volume":"10","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Hou W, Wang P et al (2018) Development of a risk grading system to identify patients with acute promyelocytic leukemia at high risk of early death. Cancer Manag Res 10:3619\u20133627. https:\/\/doi.org\/10.2147\/CMAR.S167686","journal-title":"Cancer Manag Res"},{"key":"4245_CR58","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.leukres.2009.09.017","volume":"34","author":"R Jeddi","year":"2010","unstructured":"Jeddi R, Gh\u00e9dira H, Mnif S, Gouider E, Fenaux P, Meddeb B (2010) High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia. Leuk Res 34:545\u2013547. https:\/\/doi.org\/10.1016\/j.leukres.2009.09.017","journal-title":"Leuk Res"},{"key":"4245_CR59","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2011-07-369595","volume":"119","author":"M Breccia","year":"2012","unstructured":"Breccia M, Mazzarella L, Bagnardi V et al (2012) Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. Blood 119:49\u201354. https:\/\/doi.org\/10.1182\/blood-2011-07-369595","journal-title":"Blood"},{"key":"4245_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47937-4","volume":"9","author":"JH Yoon","year":"2019","unstructured":"Yoon JH, Kim HJ, Min GJ et al (2019) Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia. Sci Rep 9:11935. https:\/\/doi.org\/10.1038\/s41598-019-47937-4","journal-title":"Sci Rep"},{"key":"4245_CR61","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.thromres.2014.02.025","volume":"133","author":"T Matsushita","year":"2014","unstructured":"Matsushita T, Watanabe J, Honda G et al (2014) Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort. Thromb Res 133:772\u2013781. https:\/\/doi.org\/10.1016\/j.thromres.2014.02.025","journal-title":"Thromb Res"},{"key":"4245_CR62","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1300874","volume":"369","author":"F Lo-Coco","year":"2013","unstructured":"Lo-Coco F, Avvisati G, Vignetti M et al (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369:111\u2013121. https:\/\/doi.org\/10.1056\/NEJMoa1300874","journal-title":"N Engl J Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04245-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04245-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04245-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T23:47:22Z","timestamp":1630540042000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04245-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,2]]},"references-count":62,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4245"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04245-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,2]]},"assertion":[{"value":"24 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the trial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Y.A. has received honoraria from Chugai Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Meiji Seika Pharma Co. Ltd., and Kyowa Hakko Kirin Co., Ltd. N.A. has received honoraria from SRL, Inc. and Nippon-Shinyaku Co., Ltd., and research funds from Chugai Pharmaceutical Co., Ltd. N.D. has received research funds from Fujimoto Pharmaceutical Co. and scholarship endowments from Pfizer Japan Inc. A.T. has received honoraria and research funds from Chugai Pharmaceutical Co., Ltd., and research funds from Kyowa Hakko Kirin Co., Ltd., and Taiho Pharmaceutical Co., Ltd. Y.K. has received honoraria from Astellas Pharma Inc. H.K. has received honoraria from Bristol-Myers Squibb, Astellas Pharma Inc., and Novartis Pharma K.K., and consulting fees from Astellas Pharma Inc., Amgen Astellas BioPharma K.K., and Daiichi Sankyo Co., Ltd., and research funds from Chugai Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Zenyaku Kogyo Co., Ltd., FUJIFILM Corporation, Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Eisai Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., Novartis Pharma K.K., Sumitomo Dainippon Pharma Co., Ltd., Sanofi K.K., and Celgene Corporation. I.M. has received honoraria from Pfizer Japan Inc., research funds from Chugai Pharmaceutical Co., Ltd., and scholarship endowments from Chugai Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd. Y.M. has honoraria from Novartis Pharma K.K., Sumitomo Dainippon Pharma Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Nippon Shinyaku Co., Ltd., and scholarship endowments from Chugai Pharmaceutical Co., Ltd. The other authors have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}